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Background: Recent reports show that R70Q and L/C91M amino acid substitutions in the core from different
hepatitis C virus (HCV) genotypes have been associated with variable responses to interferon (IFN) and ribavirin
(RBV) therapy, as well to an increase of hepatocellular carcinoma (HCC) risk, liver steatosis and insulin resistance (IR).
Mutations in NS5B have also been associated to IFN, RBV, nucleoside and non-nucleoside inhibitors drug resistance.
The prevalence of these mutations was studied in HCV RNA samples from chronically HCV-infected drug-naïve
patients.
Methods: After amplification of core and NS5B region by nested-PCR, 12 substitutions were analyzed in 266
Venezuelan HCV isolates subtype 1a, 1b, 2a, 2c, 2b, 2j (a subtype frequently found in Venezuela) and 3a (n = 127
and n= 228 for core and NS5B respectively), and compared to isolates from other countries (n = 355 and n= 646 for
core and NS5B respectively).
Results: R70Q and L/C91M core substitutions were present exclusively in HCV G1b. Both substitutions were more
frequent in American isolates compared to Asian ones (69% versus 26%, p < 0.001 and 75% versus 45%, p < 0.001
respectively). In Venezuelan isolates NS5B D310N substitution was detected mainly in G3a (100%) and G1a (13%),
this later with a significantly higher prevalence than in Brazilian isolates (p = 0.03). The NS5B mutations related to
IFN/RBV treatment D244N was mainly found in G3a, and Q309R was present in all genotypes, except G2. Resistance
to new NS5B inhibitors (C316N) was only detected in 18% of G1b, with a significantly lower prevalence than in
Asian isolates, where this polymorphism was surprisingly frequent (p < 0.001).
Conclusions: Genotypical, geographical and regional differences were found in the prevalence of substitutions in
HCV core and NS5B proteins. The substitutions found in the Venezuelan G2j type were similar to that found in G2a
and G2c isolates. Our results suggest a high prevalence of the R70Q and L/C91M mutations of core protein for G1b
and D310N substitution of NS5B protein for the G3a. C316N polymorphism related with resistance to new NS5B
inhibitors was only found in G1b. Some of these mutations could be associated with a worse prognosis of the
disease in HCV infected patients.
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Table 1 Frequency of amino acid substitution 70Q and
91 M of core protein in HCV Venezuelan isolates







1a V 1/27 (3.7%) 0/27 (0%)
U 1/27 (3.7%) 0/27 (0%)
J 0/5 (0%) 0/5 (0%)
Ur 0/3 (0%) 0/3 (0%)
1b V 30/38 (79%) 26/38 (68%)
U 20/34 (65%) 28/34 (82%)
Am 50/72 (69%) 54/72 (75%)
J 32/80 (40%) 25/80 (31%)
Ch 7/70 (10%) 43/70 (61%)
As 39/150 (26%) 68/150 (45%)
p< 0.001 p< 0.001
2a J 0/66 (0%) 0/66 (0%)
2b V 0/3 (0%) 0/3 (0%)
J 0/32 (0%) 0/32 (0%)
2c V 0/7 (0%) 0/7 (0%)
RW 0/20 (0%) 0/20 (0%)
2j V 0/42 (0%) 0/42 (0%)
3a V 1/10 (10%) 0/10 (0%)
RW 2/18 (11%) 0/18 (0%)
V: Venezuela; U: USA; Ur: Uruguay; Am: American countries (USA and
Venezuela). As: Asian countries like Ch: China and J: Japan (including
prevalence data of Furui et al. [39], for which sequences are not available); RW:
Rest of the world. Numbers in bold refer to mutations found at higher
frequency compared to other genotypes or locations. P: Statistical significance
of prevalence of mutations in isolates from the Americas compared to Asia.
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Around 170 million persons (3% of the world popula-
tion) are infected with the hepatitis C virus (HCV).
More than 350,000 people die from HCV-related liver
diseases, including hepatocellular carcinoma (HCC),
each year [1]. In Latin America around 7 million persons
are infected with HCV and overall prevalence of HCV
antibodies in non-Amerindian populations from South
America is around 1% [2-4]. About 130 million people
in the world are chronically infected with HCV and at
risk of developing liver inflammation, fibrosis, cirrhosis
and steatosis leading to HCC [1]. Furthermore, in these
chronic patients HCV infection has an increased risk of
type-2 diabetes mellitus or insulin resistance (IR) [5].
Seven HCV genotypes, and a large number of subtypes
in each genotype, have been described. Genotypes 1, 2,
and 3 have a worldwide distribution, and their prevalence
varies according to the region of the world. In Venezuela,
genotype 1 is the most frequently detected, followed by
genotypes 2 and 3, however a significant reduction of
HCV G1b circulation was observed in the last decade,
with the increase in circulation of genotype G2j, a subtype
quite rare in other countries, including the Americas [6,7].
While a vaccine for HCV is not available, many new
antiviral agents are being tested to treat HCV infection,
such as nucleoside (NIs) and non-nucleoside (NNIs)
polymerase and protease inhibitors. The combination of
pegylated interferon alpha (IFN) and ribavirin (RBV),
plus new HCV NS3/4A serine protease inhibitors (boce-
previr or telaprevir) is the current treatment for patients
chronically infected with HCV [8]. HCV genotype is also
a predictive parameter for sustained virological response
(SVR). Infections with HCV genotype 1 are associated
with the lowest therapeutic success [9].
Within the HCV genome, core is thought to be the most
conserved protein; results of nucleotide and deduced amino
acid sequence analysis across diverse strains of HCV reveal
81–88% nucleotide and 96% amino acid sequence hom-
ology [10,11]. The core gene region plays several essential
roles in the HCV life cycle. Recent studies have revealed
that amino acid substitutions in the core region of different
HCV genotypes are associated with IR [12], increased HCC
risk [13-17], variable responses to double (IFN/RBV)
[18-24] and triple (telaprevir plus INF/RBV) therapy
[25,26], and liver steatosis [27-30]. On the other hand, the
region of the viral genome that codes for NS5B has been
described as an important target in therapy with IFN/RBV,
and nucleoside and non-nucleoside drugs [31]. Many drug-
resistance mutations induced by antiviral treatment are
located in this region of the genome [32-37].
In the present study, we analyzed core and NS5B poly-
morphisms/mutations which have been associated with
non-responsiveness or a better response to IFN/RBV
combination therapy, and/or resistance to polymeraseinhibitor drugs, HCC, liver steatosis and IR, in chronic-
ally infected drug-naïve patients from Venezuela, and
these polymorphisms/mutations were compared with
worldwide HCV isolates.
Results
Some relevant core and NS5B substitutions associated with
treatment response, as well as, with a worse prognosis of
the disease were analyzed. Four core substitutions [12-30]
and eight NS5B substitutions [32-37] were studied in 266
Venezuelan HCV isolates from chronically infected, drug-
naïve patients (n=127 and n=228 for core and NS5B
respectively), and compared to isolates from other coun-
tries (n=355 and n=646 for core and NS5B respectively).
Core mutations R70Q and L/C91M, associated with IR
[12], increased HCC risk [13-17], variable responses to
double (IFN/RBV) [18-24] and triple (teleprevir plus INF/
RBV) therapy [25,26], and liver steatosis [27,28], were
mainly found in G1b isolates. In Venezuelan isolates, 42%
carried one and 53% both substitutions (data not shown).
These mutations were significantly more frequent in
American isolates compared to Asian ones (Table 1). G1a,
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G2c and G2j a Leucine. In general, both in core and NS5B
region, G2j polymorphisms were essentially similar to
those found in G2c. Steatosis motives in core domain 3
(amino acids 182 and 186 [29,30]) were exclusive to G3a.
In NS5B region, D310N, D244N, T329I and S326G sub-
stitutions have been described to be induced by RBV treat-
ment [33]. D310N was detected mainly in G3a (100%) and
G1a (13%) Venezuelan samples (Table 2). Interestingly,
the presence of this mutation in G1a isolates was signifi-
cantly higher than that found in Brazilian isolates
(p= 0.03). D244N was only found in G3a (78% in
Venezuela). G2 harbored a Serine in this position. T329I
and S326G could only be analyzed in G2 and G3 isolates,
since the length of G1 sequences did not allow the analysis
of this region. T329I was only found in G2b isolates
(100%), T329A was frequent in G2c and G2j (93% and
90% respectively), while T329V was found in G3a (100%).
S326G was no found in the HCV isolates analyzed.
Q309R and A333E NS5B mutations, frequents in
patients with SVR and end-of-treatment response (ETR)
after INF/RB therapy [32], were also analyzed. Q309R
mutation was present in all genotypes (100% G3a, 44%
G1a and 12% G1b from Venezuela), except G2 which
harbored a Valine in this position (100% G2a, G2b, G2c
and 91% G2j). This mutation was more frequently found
in Brazilian G1a isolates compared to Venezuelan and
USA isolates (Table 2). A333E mutation, only analyzed
in Venezuelan G2 and G3 isolates, was present in most
G2 samples (100% G2a, G2b, G2c and 98% G2j from
Venezuela). G3a samples harbored Lysine or Arginine
substitution at this position.
In addition, in the NS5B region, S282T and C316Y/N
substitutions, associated to resistance to new NS5B
inhibitors (20-C-methyl modified ribonucleosides and
HCV-796, respectively) [34-37], were also analyzed.
S282T mutation (Table 2) and C316Y mutation were
not found in any of the HCV isolates analyzed. How-
ever, C316N polymorphism was only detected in 18% ofTable 2 Frequency of amino acid substitution in NS5B protein
HCV Venezuelan isolates compared to worldwide isolates
1a
Substitution (related to) V Br U V
Q309R (INF/RBV) 36/82 (44%) 67/101
(66%) p = 0.004
28/70 (40%) 7/61 (12
D310N (RBV) 11/82
(13%) p = 0.03
4/101 (4%) 3/70 (4%) 1/61 (1.6
S282T (NI) 0/82 (0%) 0/101 (0%) 0/70 (0%) 0/61 (0%
C316N (NNI) 0/82 (0%) 0/101 (0%) 0/70 (0%) 11/61 (18
V: Venezuela; Br: Brazil; LA: Other Latin-American countries (Brazil, Chile, Colombia a
in bold refer to mutations found at higher frequency compared to other genotypes
from Venezuela compared to Brazil (for Q309R and D310N) and from Venezuela anVenezuelan G1b isolates, in a similar prevalence to that
found in other Latin American countries, but with a
significantly lower frequency than those found in Japan
(Table 2).
Phylogenetic analysis was performed in order to evalu-
ate the genetic relatedness of G1 isolates harboring
D310N and C316N substitutions in the NS5B region
(Figure 1). Interestingly, most of the HCV isolates har-
boring these variants, and particularly G1a isolates with
D310N substitution, were associated in clades, displaying
more than 98% of identity. However, G1a Venezuelan
isolates harboring these mutations did not group with
the Brazilian ones. Some of the clades were composed of
isolates from one country, while one clade included iso-
lates from Venezuela and USA (Figure 1).
Others mutations that also confers resistance to others
NNIs, have been identified downstream the NS5B region
[38]. These mutations could not be analyzed in this
study, due to the length of the sequence analyzed.
Discussion
A total of 12 amino acid positions were analyzed in core
[12-30] and/or NS5B region [32-37] of Venezuelan HCV
isolates and compared to worldwide isolates. Substitu-
tions in these sites have been related either to IFN/RBV
treatment or differential susceptibility to others drugs,
and/or to a worse prognosis of the disease [12-30,32-37].
These substitutions were found in 9/12 positions ana-
lyzed, with genotypical, geographical and/or regional dif-
ferences in the prevalence of them.
R70Q and L/C91M core substitutions were found
more frequently in Venezuelan and USA G1b isolates,
compared to Asian ones. These amino acid substitutions
in core region of different HCV genotypes are associated
with increased HCC risk [13-17], variable responses to
IFN/RBV therapy [18-24], liver steatosis [27-30] and IR
[12]. Treatment with IFN/RBV has been proposed to in-
duce these amino acid mutations [23]. Another possible
explanation is that these mutations might be selectedrelated to resistance to INF/RBV and new inhibitors in
Genotypes
1b 3a
LA ASIA V LA U
%) 7/104 (6.7%) 19/335 (5.7%) 9/9 (100%) 20/22 (91%) 21/21 (100%)
%) 1/104 (1%) 3/335 (0.9%) 9/9 (100%) 20/22 (91%) 20/21 (95%)
) 0/104 (0%) 0/335 (0%) 0/9 (0%) 0/22 (0%) 0/21 (0%)
%) 18/104 (18%) 307/335
(91.6%) p < 0.001
0/9 (0%) 0/22 (0%) 0/21 (0%)
nd/or Argentina); U: USA; Asia: China, Japan, Hong Kong and Taiwan. Numbers
or locations. P: Statistical significance of prevalence of mutations in isolates




































































































Figure 1 (See legend on next page.)
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Figure 1 Phylogenetic analysis of the NS5B partial genomic region (256 nt, 8302–8556) of HCV G1 strains. Genetic distance was estimated
by Kimura 2 parameters and phylogenetic tree was constructed with the Neighbor joining method. Bootstrap values over 50% are shown in the tree.
Isolates are designated by their GenBank accession number, followed by their country of origin, except for Venezuelan ones, which are numbered and
preceded by a C. G1a sequences harboring D310N substitution were included, and a similar number of sequences not harboring these mutations,
from Venezuela (n= 23), Brazil (BRA, n= 8) and USA (n= 6). The same criteria of selection was applied to G1b sequences, respect to C316N substitution,
from Venezuela (n= 23), Brazil (n= 6) and Asia (n= 7 from HK: Hong Kong, JAP: Japan and CHI: China). Sequences grouped in clades containing D310N
or C316N substitutions are shown in brackets. Percent identities over 98% are shown for these clades.
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selective pressure of endogenous IFN [39]. The relatively
high frequency of these mutations in patients not treated
with IFN/RBV might be associated to the transmission
of HCV isolates from treated patients. In addition, this
relative high frequency in Latin America warrants fur-
ther follow up studies in patients harboring one or two
of these mutations. Steatosis motives in core domain 3
were exclusive to G3a, as previously reported [29].
Some mutations have been described in the NS5B re-
gion and appeared to be generated during IFN/RBV treat-
ment, probably because of the mutagenic effect of RBV
[33]. D310N was detected in all G3a isolates. Interestingly,
the frequency of this mutation was higher in Venezuelan
G1a compared to Brazilian and USA isolates. Phylogenetic
analysis of G1a isolates showed that the isolates carrying
D310N were grouped in clades with high genetic related-
ness, in agreement with the hypothesis of networks of
transmission between non-treated patients infected with
HCV isolates from a treated patient.
In addition, some of these mutations have been found
more frequently in viruses infecting patients with sus-
tained virological response (SVR) or during end-of-
treatment response (ETR), in which the virus has been
persistently or at least temporarily eliminated [32]. From
these, the Q309R and A333E mutations were analyzed
in this study. In Venezuelan isolates Q309R was present
in all genotypes except G2, very frequent in G3 and rare
in G1b. In G1a the frequency of this mutation was simi-
lar in Venezuelan and USA isolates, but significantly
lower than those found in Brazil. Instead, A333E was
frequent in G2 and rare in G3, while it could not be
analyzed in G1. These results are in agreement with the
frequency found in other countries [40]. The presence of
these amino acid substitutions might be related to the
relative susceptibility to IFN/RBV of G2 and G3 com-
pared to G1.
S282T mutation in the NS5B polymerase is known to
confer resistance to the inhibitor 20-C-methyl modified
ribonucleosides [34] with a decrease viral fitness [35].
This mutation was not present in the isolates analyzed
in this study.
For NNIs, resistance mutations may also occur as nat-
ural variants more frequently in patients infected with a
specific subtype. For example, the C316Y mutation inNS5B is associated most frequently with resistance to
HCV-796 [36]. Furthermore, C316N also reduces sensi-
tivity to HCV796 in vitro and this polymorphism is
observed in many patients infected with HCV subtype
1b [41-43]. While C316Y mutation was not present in
the isolates analyzed, C316N variant was detected in
18% of Venezuelan G1b isolates, with a significantly
lower prevalence than in Asian isolates, where this mu-
tation was found at high frequency (Table 2). Again,
phylogenetic analysis showed that Venezuelan G1b iso-
lates carrying the C316N were generally grouped in
clades, displaying high genetic relatedness.
Two major clades have been described inside G1a iso-
lates worldwide [44]. Brazilian isolates belong mainly to
one of these clades [45], and even form a cluster inside
this clade [46]. Venezuelan HCV isolates do not group
together with Brazilian isolates (Figure 1). These results
suggest that important regional variations might be
found in HCV isolates circulating in South America. An
example of this is the predominant circulation of G2j
among the G2 isolates circulating in Venezuela, and not
found in other neighboring countries [7].
Conclusions
Genotypical, geographical and regional differences were
found in the prevalence of substitutions in HCV core
and NS5B proteins. The substitutions found in the
Venezuelan G2j type were similar to that found in G2a
and G2c isolates. Our results suggest a high prevalence
in Venezuela of the R70Q and L/C91M mutations of
core protein for G1b and D310N substitution of NS5B
protein for the G3a. As expected, C316N polymorphism,
associated to resistance to NNIs was only found in G1b,
and mutation S282T to NIs was absent. However, the
presence of mutations associated to a worse prognosis of
the disease in HCV-infected patients warrants further
studies to analyze their impact in the clinical outcome of
this disease in Venezuela.
Methods
Blood samples
Serum samples were collected from 1997 to 2010, from
HCV-infected untreated patients after written informed
consent, and stored at −30°C until use. This study was
approved by the Bioethical Committee of Instituto
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of 127 Venezuelan samples (27 infected with HCV-1a, 38
HCV-1b, 3 HCV-2b, 7 HCV-2c, 42 HCV-2j and 10 with
HCV-3a) were processed for core amplification (57.5%
male) and 228 (82 infected with HCV-1a, 61 HCV-1b, 1
with HCV-2a, 13 HCV-2b, 9 HCV-2c, 53 HCV-2j and 9
with HCV-3a) for NS5B amplification (58.3% male).
PCR and sequencing
HCV RNA was extracted from human plasma sample
using a QIAampW Viral Mini Kit (QIAGEN, Hilden
Germany) and reverse-transcribed to complementary
DNA using MMLV Reverse Transcriptase (Invitrogen life
technologies, USA), according to the manufacturers
protocol. HCV genotype was determined by direct se-
quencing and phylogenetic analysis of a polymerase chain
reaction-amplified product from the 5' non-coding region
[6], core and/or NS5B [7]. The NS5B amplicons were gen-
erated previously [7]. The core amplified PCR products
were purified by using the QIAquick PCR Purification Kit
(Qiagen) and then subjected to direct nucleotide sequen-
cing. In all cases, both sense and antisense inner primers
were used for sequencing and all sequences were per-
formed by Macrogen Service Center, Seoul, Korea. A total
of 127 core sequences were analyzed: 49 obtained previ-
ously [7] and 79 from this study.
Determination and analysis of core and NS5B amino acid
sequence
Amino acid sequences were deduced and aligned using
MEGA 4.0.2. The NS5B sequences [GenBank accession
numbers HM777048-HM777357] and core sequences
[GenBank accession numbers HM777360 -HM777430 and
JQ924868-JQ924946] of Venezuelan HCV-infected naïve
patients were analyzed. The sequences of each genotype
from other countries were obtained from GenBank and
HCV database (http:VHC.lanl.gov/content/VHC-db/index).
Phylogenetic analysis
Sequence alignment performed by the global alignment
algorithm, using DNAman 5.2.2 (Lynnon Bio Soft,
Canada). Phylogenetic analysis was performed by the
Neighbor Joining method (1000 bootstrap replicas, with
genetic distances estimated with Kimura 2 parameters
correction).
Statistical analysis
Statistical differences were evaluated by the Chi-Squares
test with Yates correction, or Fisher Exact test, according
to a computerized Epi Info program, version 3.5.3 (Centers
for Disease Control and Prevention, Atlanta, GA).
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